Skip to main content

Table 3 Metabolic risk factors in metabolic syndrome patients with Irbesartan treatment alone or in combination with HCTZ

From: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

   Irbesartan in patients with the metabolic syndrome1 Irbesartan/12.5 mg HCT in patients with the metabolic syndrome1
Components of the Met. Syn. Baseline 3 months 9 months Reduction † Baseline 3 months 9 months Reduction †
Blood pressure mean ± SD mean ± SD mean ± SD   mean ± SD mean ± SD mean ± SD  
systolic mmHg 159.1 ± 12.9 137.8* ± 11.2 132.8* ± 10.1 -26.3 161.3 ± 13.2 139.0* ± 11.2 133.8* ± 10.1 -27.5
diastolic mmHg 93.4 ± 8.6 82.8* ± 7.2 80.4* ± 6.6 -13.0 95.0 ± 8.6 83.8* ± 7.4 80.9* ± 6.6 -14.1
Fasting plasma                
glucose mg/dL 118.3 ± 29.9 111.8* ± 26.0 109.9* ± 25.1 -8.4 122.9 ± 29.8 115.4* ± 26.0 112.9* ± 24.7 -10.0
Abdominal obesity                
men cm 109.9 ± 13.0 108.4* ± 12.2 107.5* ± 11.9 -2.4 112.0 ± 12.9 110.3* ± 12.3 108.8* ± 12.7 -3.2
women cm 99.3 ± 14.3 98.3* ± 14.3 98.1* ± 14.2 -1.2 101.5 ± 14.7 100.8* ± 14.7 99.8* ± 14.4 -1.7
Triglycerides mg/dL 212.3 ± 61.2 194.2* ± 56.7 183.7* ± 52.1 -28.6 221.5 ± 63.0 198.4* ± 55.3 187.4* ± 52.6 -34.1
HDL cholesterol                
men mg/dL 42.2 ± 7.7 44.6* ± 7.3 45.8* ± 7.2 3.6 41.4 ± 7.5 44.0* ± 7.0 45.4* ± 6.8 4.0
women mg/dL 45.0 ± 7.2 47.8* ± 6.8 48.8* ± 6.5 3.8 44.2 ± 7.4 46.4* ± 6.9 47.6* ± 6.8 3.4
  1. 1 doctors' diagnosis; statistical test applied: t-test; * p < 0.0001; ** p < 0.05; † reduction versus baseline